Public funding for ovarian cancer drug Elahere moves closer to approval
The Pan-Canadian Pharmaceutical Alliance and the manufacturer of Elahere have reached a funding agreement. This targeted chemotherapy for FRα-positive, platinum-resistant ovarian cancer is now recommended for public reimbursement by Canada’s Drug Agency. Provincial and territorial governments must now finalize the process to include the drug in their respective public plans.
If you treat patients with platinum-resistant ovarian cancer, this agreement moves the drug closer to being covered by provincial public drug plans.
Ask about this brief
Answers are written by AI from this brief and can be wrong. Check the original source before you act.
2 free questions a day without an account. Members ask as often as they like, free.
Not medical, legal or immigration advice. Questions are kept anonymously to improve our briefs.
Read the original
News source: Public funding for ovarian cancer drug Elahere moves closer to approval (opens in a new tab) — The Canadian Press (CityNews)

